Greenwich LifeSciences Inc

Previous wording

The following discussion and analysis is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management.

Current wording

The following discussion and analysis is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the condensed financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management.

Previous wording

To date, we have not generated any revenue and we have incurred net losses. Our net losses were approximately $8.9 million and $7.8 million for the years ended December 31, 2023 and 2022, respectively and $2.5 million and $2.1 million for the three months ended March 31, 2024 and 2023, respectively.

Current wording

To date, we have not generated any revenue and we have incurred net losses. Our net losses were approximately $8.9 million and $7.8 million for the years ended December 31, 2023 and 2022, respectively and $5.1 million and $3.8 million for the six months ended June 30, 2024 and 2023, respectively.

Previous wording

Research and development expenses increased by $366,606, or 20%, to $2,194,513 for the three months ended March 31, 2024 from $1,827,907 for the three months ended March 31, 2023. The increase was primarily the result of an increase in clinical expenses.

Current wording

Research and development expenses increased by $928,306 or 67%, to $2,307,873 for the three months ended June 30, 2024 from $1,379,567 for the three months ended June 30, 2023. The increase was primarily the result of an increase in clinical and manufacturing expenses.

Previous wording

General and administrative expenses decreased by $70,487, or 17%, to $342,688 for the three months ended March 31, 2024 from $413,175 for the three months ended March 31, 2023.

Current wording

General and administrative expenses decreased by $14,728, or 4%, to $353,531 for the three months ended June 30, 2024 from $368,259 for the three months ended June 30, 2023.

Previous wording

Since our inception in 2006, we have devoted most of our cash resources to research and development and general and administrative activities. We have not yet achieved commercialization of our product and have a cumulative net loss from our operations. We will continue to incur net losses for the foreseeable future. Our financial statements have been prepared assuming that we will continue as a going concern.

Current wording

Since our inception in 2006, we have devoted most of our cash resources to research and development and general and administrative activities. We have not yet achieved commercialization of our product and have a cumulative net loss from our operations. We will continue to incur net losses for the foreseeable future. Our condensed financial statements have been prepared assuming that we will continue as a going concern.

Previous wording

We will require additional capital to meet our long-term operating requirements. We expect to raise additional capital through the sale of equity and/or debt securities; however, there is no assurance that we will be successful at raising additional capital in the future. If our plans are not achieved and/or if significant unanticipated events occur, we may have to further modify our business plan, which may require us to raise additional capital. As of March 31, 2024 and December 31, 2023, our principal source of liquidity was our cash, which totalled $5,505,975 and $6,989,424, respectively, and additional loans and accrued unreimbursed expenses from related parties. Historically, our principal sources of cash have included proceeds from the sale of common stock and preferred stock and related party loans. Our principal uses of cash have included cash used in operations. We expect that the principal uses of cash in the future will be for continuing operations, funding of research and development, including our clinical trials, and general working capital requirements.

Current wording

We will require additional capital to meet our long-term operating requirements. We expect to raise additional capital through the sale of equity and/or debt securities; however, there is no assurance that we will be successful at raising additional capital in the future. If our plans are not achieved and/or if significant unanticipated events occur, we may have to further modify our business plan, which may require us to raise additional capital. As of June 30, 2024 and December 31, 2023, our principal source of liquidity was our cash, which totaled $7,224,875 and $6,989,424, respectively, and additional loans and accrued unreimbursed expenses from related parties. Historically, our principal sources of cash have included proceeds from the sale of common stock and preferred stock and related party loans. Our principal uses of cash have included cash used in operations. We expect that the principal uses of cash in the future will be for continuing operations, funding of research and development, including our clinical trials, and general working capital requirements. The Company’s existing cash resources are expected to provide sufficient funds to carry the Company’s planned operations over the next 12 months from the date these condensed financial statements were issued.

Previous wording

Cash Flow Activities for the Three Months Ended March 31, 2024 and 2023

Current wording

Cash Flow Activities for the Six Months Ended June 30, 2024 and 2023

Previous wording

We incurred net losses of$2,473,195 and $2,124,902 during the three month periods ended March 31, 2024 and 2023, respectively. The increase was primarily the result of an increase in cash compensation, clinical, and manufacturing expenses.

Current wording

We incurred net losses of $5,079,877 and $3,753,275 during the six month periods ended June 30, 2024 and 2023, respectively. The increase was primarily the result of an increase in clinical and manufacturing expenses.

Previous wording

Net cash used in operating activities was $1,782,565 for the three months ended March 31, 2024 and $1,556,807 for the three months ended March 31, 2023.

Current wording

Net cash used in operating activities was $2,830,405 for the six months ended June 30, 2024 and $2,523,784 for the six months ended June 30, 2023.

Previous wording

We did not use or generate cash from investing activities during the three months ended March 31, 2024 and 2023.

Current wording

We did not use or generate cash from investing activities during the six months ended June 30, 2024 and June 30, 2023.

Previous wording

Between January 1, 2024 and March 31, 2024, the Company completed At The Market (“ATM”) offerings pursuant to its ATM agreement with Jefferies, in which it issued and sold a total of 27,117 shares of its common stock at an average offering price of $12.26 per share for gross proceeds of$332,351 and net proceeds of$299,116, after deducting underwriting discounts and commissions and offering expenses borne by the Company, which totalled$33,235.

Current wording

Between January 1, 2024 and June 30, 2024, the Company sold shares of its common stock pursuant to its ATM agreement with Jefferies, in which it issued and sold a total of 44,697 shares of its common stock at an average offering price of $14.07 per share for gross proceeds of $628,732 and net proceeds of $565,858, after deducting underwriting discounts and commissions and offering expenses borne by the Company, which totaled $62,874.

Previous wording

Between April 1, 2024 and May 8, 2024, the Company completed At The Market (“ATM”) offerings pursuant to its ATM agreement with Jefferies, in which it issued and sold a total of 4,713 shares of its common stock at an average offering price of $17.08 per share for gross proceeds of$80,482 and net proceeds of$72,434, after deducting underwriting discounts and commissions and offering expenses borne by the Company, which totalled$8,049.

Current wording

Between July 1, 2024 and August 2, 2024, the Company sold shares of its common stock pursuant to its ATM agreement with Jefferies, in which it issued and sold a total of 76,966 shares of its common stock at an average offering price of $17.06 per share for gross proceeds of $1,312,692 and net proceeds of $1,181,424, after deducting underwriting discounts and commissions and offering expenses borne by the Company, which totaled $131,269.

Previous wording

As of March 31, 2024, we did not have any material contractual obligations, other than employment and shareholder agreements and the license for GP2 from HJF.

Current wording

As of June 30, 2024, we did not have any material contractual obligations, other than employment and shareholder agreements and our license for GP2 from HJF.

Previous wording

Our financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses in the periods presented.

Current wording

Our condensed financial statements are prepared in conformity with U.S. GAAP, which require the use of estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the condensed financial statements, and the reported amounts of expenses in the periods presented.

Previous wording

We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards.

Current wording

We have chosen to take advantage of the extended transition periods available to emerging growth companies under the JOBS Act for complying with new or revised accounting standards until those standards would otherwise apply to private companies provided under the JOBS Act. As a result, our condensed financial statements may not be comparable to those of companies that comply with public company effective dates for complying with new or revised accounting standards.